73,416 Shares in Inhibrx Biosciences, Inc. $INBX Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 73,416 shares of the company’s stock, valued at approximately $6,956,000.

A number of other hedge funds have also added to or reduced their stakes in INBX. Persistent Asset Partners Ltd bought a new position in Inhibrx Biosciences in the 4th quarter worth $27,000. Quantbot Technologies LP purchased a new stake in shares of Inhibrx Biosciences in the 2nd quarter worth about $68,000. BNP Paribas Financial Markets boosted its stake in shares of Inhibrx Biosciences by 71.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after purchasing an additional 789 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $66,000. Finally, Janney Montgomery Scott LLC increased its position in shares of Inhibrx Biosciences by 16.6% during the first quarter. Janney Montgomery Scott LLC now owns 6,406 shares of the company’s stock valued at $431,000 after buying an additional 911 shares during the period. 82.46% of the stock is owned by hedge funds and other institutional investors.

Inhibrx Biosciences Price Performance

Shares of NASDAQ INBX opened at $123.93 on Friday. Inhibrx Biosciences, Inc. has a fifty-two week low of $26.19 and a fifty-two week high of $155.29. The company has a 50 day simple moving average of $93.69 and a two-hundred day simple moving average of $90.40. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -13.96 and a beta of 3.51. The company has a debt-to-equity ratio of 12.58, a quick ratio of 5.07 and a current ratio of 5.07.

Inhibrx Biosciences (NASDAQ:INBX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). Analysts expect that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current fiscal year.

Inhibrx Biosciences News Summary

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright’s bullish rating and price target indicate confidence in Inhibrx’s longer-term prospects, representing the primary positive catalyst in the reports.
• Neutral Sentiment: The analyst projects continued quarterly losses but expects losses to narrow from approximately $8.93 per share in fiscal 2026 to $8.47 per share in fiscal 2027. Estimates include losses of $2.14 per share in Q3 2026 and $2.30 per share in Q4 2026, followed by quarterly losses ranging from $2.02 to $2.22 in 2027.
• Negative Sentiment: Inhibrx remains unprofitable, and the projected losses could limit near-term enthusiasm despite the favorable analyst rating. The company also recently reported an earnings-per-share miss, underscoring ongoing execution and development risks.

Analysts Set New Price Targets

A number of research firms recently issued reports on INBX. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. HC Wainwright initiated coverage on Inhibrx Biosciences in a research report on Monday. They set a “buy” rating and a $245.00 price objective on the stock. Wall Street Zen downgraded Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a report on Monday, August 17th. Finally, Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Inhibrx Biosciences has an average rating of “Moderate Buy” and an average target price of $197.50.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.